CLINICAL USE

Anti-epileptic agent Neuropathic pain Generalised anxiety disorder

DOSE IN NORMAL RENAL FUNCTION

150–600 mg daily in 2 or 3 divided doses

PHARMACOKINETICS

  • Molecular weight                           :159.2
  • %Protein binding                           :0
  • %Excreted unchanged in urine     : 92–99
  • Volume of distribution (L/kg)       :0.56
  • half-life – normal/ESRD (hrs)      :5–6.5/ Increased

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

    30–60 Initial dose 75 mg daily and titrate according to tolerability and response15–30 Initial dose 25–50 mg daily and titrate according to tolerability and response<15 Initial dose 25 mg daily and titrate according to tolerability and response

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Dialysed. Dose as in GFR<15 mL/min
  • HD                     :Dialysed. Dose as in GFR<15 mL/min
  • HDF/high flux   :Dialysed. Dose as in GFR<15 mL/min
  • CAV/VVHD      :Dialysed. Dose as in GFR=15–30 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • None known

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    OTHER INFORMATION

    Oral bioavailability >90% 50% of dose is removed after a 4 hour haemodialysis sessionUse with caution in people with severe congestive heart failure. May cause reversible deterioration in renal function.

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia